GlassScriptPhysician profile
Stacie A Gilroy
NPI 1619906864
$4,855.29
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,648 · 2022: $1,684 · 2023: $1,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,523.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $604.31 | 2021-2023 | |
| Lilly USA, LLC | $427.43 | 2021-2023 | Jardiance, Mounjaro, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $409.89 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $385.91 | 2021-2023 | Airsupra, Bevespi Aerosphere, Farxiga |
| Novo Nordisk INC | $319.14 | 2021-2023 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $242.02 | 2022-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $208.02 | 2021-2023 | Invega Sustenna, Xarelto |
| Kowa Pharmaceuticals America, INC. | $173.34 | 2021-2023 | Livalo, Seglentis |
| Biohaven Pharmaceutical Holding Company LTD. | $167.59 | 2022 | |
| Grifols USA, LLC | $120.69 | 2022-2023 | Prolastin-C Liquid |
| Pfizer INC. | $120.62 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $119.92 | 2021-2023 | |
| Glaxosmithkline, LLC. | $116.92 | 2021-2023 | Trelegy Ellipta, Shingrix, Bexsero |
| Merck Sharp & Dohme LLC | $106.66 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.06 | 2021-2023 | Trintellix |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacie Gilroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.